Cencora, Inc. (COR): If It Was Down, I’d Say “Double Down And Buy,” Says Jim Cramer

We recently published Jim Cramer’s Fresh 14 Stocks & Thoughts About Market Performance. Cencora, Inc. (NYSE:COR) is one of the stocks Jim Cramer recently discussed.

Cencora, Inc. (NYSE:COR) is an American pharmaceutical and healthcare services provider. It is a rare stock in its peers that is in the green this year. Cencora, Inc. (NYSE:COR)’s shares have gained 32.30% year-to-date as the firm has benefited from being insulated against tariffs and the Most Favored Nation drug policy. The strong backdrop has also allowed it to raise its earnings guidance. In May, Cencora, Inc. (NYSE:COR) raised its profit per share guidance to $15.70 and $15.95 from an earlier $15.30 to $15.60. In his comments, Cramer shared that he’d buy the stock even if it dipped by 50%:

“No I mean look it’s not the hospitals which always win and it’s certainly not the middlemen. I mean if you told me Cencora was down 50%, I’d say why don’t you double down and buy a lot.”

Previously, the CNBC host discussed Cencora, Inc. (NYSE:COR) and its peers in detail:

“These stocks, namely Cardinal Health, Cencora, and McKesson, are seemingly perpetual residents on the new high list. Over the long haul, they’re some of the best performers out there, and they’ve done great this year, as is pretty much always the case. And yet, doesn’t it always feel like the drug distributors are just one bad day away from falling apart… The last quarter from the major drug distributors came from McKesson, and that was last Thursday night, which delivered yet another very strong set of numbers… Like the others. McKesson had a top-line miss, in this case, actually a pretty sizable one, but still delivered a significant earnings beat, and gave a higher-than-expected full-year earnings forecast in a vacuum.

I think the McKesson quarter was strong enough to spark a nice rally for the stock last Friday. But we don’t live in a vacuum, do we?… The big negative development for the drug distributors came midweek when Politico reported that President Trump would be reviving an effort to dramatically cut drug costs by adopting what’s known as the Most-Favored-Nation pricing for Medicare…

As a result, all the drug distributors are either flat or slightly lower this week… so that’s the conundrum with these middlemen, Cardinal, Cencora, and McKesson are all doing incredibly well, but like I said before, there always seems to be a threat that they could be regulated out of existence.”

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.